The FDA has approved labeling changes for Celebrex (celecoxib) based on the results of the Celecoxib Long-term Arthritis Safety Study (CLASS). CLASS was a prospective double-blind randomized safety trial that evaluated approximately 4000 patients with osteoarthritis (OA) and rheumatoid arthritis (RA) treated with Celebrex 400 mg twice a day (twice the highest approved dose of Celebrex to treat RA) compared to approximately 4000 patients treated with standard doses of ibuprofen or diclofenac (nonsteroidal anti-inflammatory drugs.) The use of low-dose aspirin for cardiovascular prophylaxis (up to 325 mg/day) was permitted during the study
See all
